What's Happening?
FACTOR X, a new med-tech and cosmetics startup, has been launched by Israeli researchers Dr. Inbal Gat and Dr. Shira Orr, along with businesswoman Bar Refaeli and entrepreneur Eran Orr. The Tel Aviv-based company aims to develop a system that delivers
active ingredients directly into targeted skin cells. The startup has completed a pre-seed funding round and is now raising seed financing to expand its research and development efforts. FACTOR X's platform is based on longevity research and is designed to deliver active compounds to specific structures within selected cells, potentially influencing aging processes inside skin cells.
Why It's Important?
The launch of FACTOR X represents a significant advancement in the field of skincare and longevity medicine. By focusing on delivering active ingredients directly into skin cells, the company aims to address the biological mechanisms of aging rather than just treating visible effects. This approach could lead to breakthroughs in skincare, offering new solutions for issues like pigmentation, hair restoration, and skin-cell repair. The involvement of high-profile figures like Bar Refaeli and the scientific expertise of Dr. Gat and Dr. Orr add credibility and visibility to the venture, potentially attracting interest from global cosmetics companies.
What's Next?
FACTOR X plans to use its seed funding to continue developing its technology, expand testing, and pursue strategic partnerships with global beauty companies. The company aims to establish a laboratory in Israel and further refine its cellular delivery technology. As the platform progresses, FACTOR X intends to integrate its technology into existing cosmetic products, potentially licensing it to international cosmetics companies. This business-to-business model could facilitate widespread adoption of the technology, allowing established brands to incorporate it into their product lines.
